INTRODUCTION {#s1}
============

One of the most surprising advances in understanding the mechanisms of gene regulation in health and disease has been the discovery of microRNA (miRNA) \[[@R1]\].

MiRNAs are short (usually 21--23 nucleotides in length), evolutionarily conserved, noncoding RNA molecules that exert post-transcriptional regulation via binding to complementary sequences in the 3′-untranslated region (3′ UTR) or 5′-untranslated region (5′UTR) of target messenger RNAs (mRNAs) \[[@R2], [@R3]\]. Upon miRNA binding, the mRNA transcript is degraded or its translation inhibited \[[@R4]\]. Thus, miRNAs play a crucial role in gene expression, affecting many normal and abnormal cellular processes such as cell differentiation, proliferation, metabolism, apoptosis, and tumorigenesis \[[@R5], [@R6]\].

Breast cancer (BC) is the most common type of cancer affecting women worldwide. Although its etiology is multifactorial, its development and outcome are especially influenced by genetic factors. In this regard, several studies pointed out that alterations in miRNAs may contribute to the pathogenesis of BC \[[@R6], [@R7]\]. Since approximately 50% of miRNA genes are located in cancer-related chromosomal regions \[[@R8]\], in recent years their usefulness as biomarkers to evaluate cancer risk has been the subject of intense research.

Single nucleotide polymorphisms (SNPs) represent the most common form of genetic variation. When present in miRNA genes, SNPs may influence miRNAs' properties by altering their expression, maturation, and/or function \[[@R9]\], and may thus increase the risk of cancer, or influence its progression \[[@R10], [@R11]\].

Among several common miRNA SNPs purportedly related with BC risk, the association of rs2910164 in miR-146a, rs11614913 in miR-196a2, and rs3746444 in miR-499 and BC risk remains inconclusive. For instance, Bansal et al. found that the heterozygous variant of rs2910164 in miR-146a is associated with reduced risk of BC \[[@R12]\], while a separate report indicated associations for rs11614913 in miR-196a2 and rs3746444 in miR-499 \[[@R13]\]. Nevertheless, some studies reported that these polymorphisms were not related to BC risk \[[@R14], [@R15]\]. Therefore, in order to evaluate the association of these three miRNA SNPs and BC susceptibility, we performed this meta-analysis by systematically summarizing published data.

RESULTS {#s2}
=======

Characteristics of the studies {#s2_1}
------------------------------

Based on the search strategy, a total of 217 articles were chosen from PubMed and EMBASE databases. After screening the title and abstract, 192 articles uncorrelated with BC risk and miR-146a/-196a2/-499 SNPs were excluded. 25 articles were then evaluated in detail, and 8 articles were further excluded, among which 3 were meeting reports \[[@R16]--[@R18]\], 2 had inadequate information to calculate ORs \[[@R19], [@R20]\], and the other 3 were not case-control studies \[[@R21]--[@R23]\]. Finally, 17 eligible articles were included in our meta-analysis \[[@R12]--[@R15], [@R24]--[@R36]\] (Figure [1](#F1){ref-type="fig"}). The characteristics and the NOS quality assessment of the included studies are outlined in Table [1](#T1){ref-type="table"} and Figure [2](#F2){ref-type="fig"}. We categorized races as Asian (Chinese, Iranian, and Indian), Caucasian (Australian, Arab, Brazilian, French, Italian, German, and American), and Mixed (Chilean, and Non-Caucasian Brazilian) based on the original information from each study. In these articles, the distribution of genotypes in the controls were consistent with HWE in most of the studies, but some parts of the data in Qi's, Omrani's, Catucci's, Ma's, Bansal's, Alshatwi's, and Linhares' studies didn\'t meet HWE. In Catucci\'s study, the subjects were from two countries, whereas in Linhares' study the samples in the case and control groups belonged to Caucasian and non-Caucasian populations, so we treated them as independent studies. There were nine studies containing 4,441 cases and 3,899 controls for miR-146a rs2910164 \[[@R12]--[@R15], [@R24]--[@R26], [@R28], [@R36]\]; twelve studies involving 5,792 cases and 7,159 controls for miR-196a2 rs11614913 \[[@R13], [@R14], [@R27]--[@R35]\]; and seven studies including 4,019 cases and 4,683 controls for miR-499 rs3746444 \[[@R13], [@R14], [@R24], [@R28], [@R30], [@R35]\]. Genotype distributions in controls were in accord with HWE in all included studies. A variety of genotyping methods were applied including TaqMan, PCR-RFLP, MassARRAY, and HRM.

![Study selection process](oncotarget-08-68809-g001){#F1}

###### The baseline characteristics for included studies

  Study ID                           Year   Country     Race            Genotyping   Source of Control   Case        Control   HWE (*P*)                                     
  ---------------------------------- ------ ----------- --------------- ------------ ------------------- ----------- --------- ----------- -------- ------ ----- ----- ----- -------
  **miR146a (rs2910164 G \> C)**            **Total**   **GG**          **GC**       **CC**              **Total**   **GG**    **GC**      **CC**                            
  Upadhyaya                          2016   Australia   Caucasian       HRM          PB                  546         325       193         28       246    112   99    35    0.091
  He                                 2015   China       Asian           MassARRAY    HB                  450         75        242         133      450    72    225   153   0.478
  Bansal                             2014   India       Asian           PCR-RFLP     PB                  121         82        35          4        164    84    72    8     0.130
  Ma                                 2013   China       Asian           MassARRAY    HB                  192         35        94          63       191    34    93    64    0.983
  Alshatwi                           2012   Arabia      Caucasian       TaqMan       HB                  100         48        50          2        100    51    46    3     0.051
  Garcia                             2011   France      Caucasian       Taqman       PB                  1130        676       388         66       596    352   220   24    0.150
  Catucci                            2010   Germany     Caucasian       Taqman       PB                  805         451       304         50       904    536   318   50    0.753
  Pastrello                          2010   Italy       Caucasian       Taqman       PB                  88          53        30          5        155    90    59    6     0.332
  Hu                                 2009   China       Asian           PCR-RFLP     PB                  1009        165       515         329      1093   180   551   362   0.221
  **miR196a2 (rs11614913 C \> T)**          **Total**   **CC**          **CT**       **TT**              **Total**   **CC**    **CT**      **TT**                            
  Morales                            2016   Chile       Mix             TaqMan       HB                  440         192       191         57       807    342   351   114   0.121
  Dai                                2016   China       Asian           MassARRAY    HB                  560         197       265         98       583    155   284   144   0.540
  Qi                                 2015   China       Asian           TaqMan       HB                  321         34        119         168      290    17    88    185   0.141
  He                                 2015   China       Asian           MassARRAY    HB                  450         81        233         136      450    93    223   134   0.990
  Omrani                             2014   Iran        Asian           PCR- RFLP    PB                  236         218       18          0        203    178   25    0     0.350
  Zhang                              2012   China       Asian           PCR- RFLP    PB                  248         11        89          148      243    17    93    133   0.893
  Linhares                           2012   Brazil      Non-Caucasian   TaqMan       HB                  63          11        29          23       114    33    51    30    0.264
  Jedlinski                          2011   Australia   Caucasian       PCR- RFLP    PB                  187         68        86          33       171    58    82    31    0.830
  Catucci                            2010   Italy       Caucasian       Taqman       PB                  751         334       330         87       1243   532   550   161   0.315
  Catucci                            2010   Germany     Caucasian       Taqman       PB                  1101        432       512         157      1496   584   696   216   0.711
  Hu                                 2009   China       Asian           PCR-RFLP     PB                  1009        239       483         287      1093   218   517   358   0.207
  Hoffman                            2009   USA         Caucasian       MassARRAY    HB                  426         181       209         36       466    166   229   71    0.583
  **miR499 (rs3746444 A \> G)**             **Total**   **AA**          **AG**       **GG**              **Total**   **AA**    **AG**      **GG**                            
  Dai                                2016   China       Asian           MassARRAY    HB                  560         407       135         18       583    463   109   11    0.130
  Qi                                 2015   China       Asian           TaqMan       HB                  321         152       117         52       290    141   112   37    0.053
  He                                 2015   China       Asian           MassARRAY    HB                  450         184       177         89       450    203   188   59    0.143
  Alshatwi                           2012   Arabia      Caucasian       TaqMan       HB                  100         30        62          8        100    45    40    15    0.227
  Catucci                            2010   Italy       Caucasian       Taqman       PB                  756         414       295         47       1242   704   452   86    0.250
  Catucci                            2010   Germany     Caucasian       Taqman       PB                  823         536       250         37       925    601   290   34    0.893
  Hu                                 2009   China       Asian           PCR-RFLP     PB                  1009        707       258         44       1093   816   248   29    0.057

Notes: PB: Population-based; HB: Hospital-based.

![Quality assessment of included studies according to the Newcastle-Ottawa Scale (NOS) criteria)](oncotarget-08-68809-g002){#F2}

Association between miRNA-146a rs2910164 polymorphism and BC susceptibility {#s2_2}
---------------------------------------------------------------------------

We firstly assessed the association between miRNA-146a rs2910164 polymorphism and BC susceptibility. Significant heterogeneity was identified by *Q*-test and *I^2^* statistic under all genetic models except the heterozygote. Therefore, except for the latter, the random-effects model was used for all models. No significant associations were identified for any genetic model (C vs. G: OR = 0.90, 95% CI: 0.78--1.05; CC vs. GG: OR = 0.86, 95% CI: 0.62--1.20; GC vs. GG: OR = 0.95, 95% CI: 0.86--1.05; CC + GC vs. GG: OR = 0.89, 95% CI: 0.75--1.07; CC vs. GG + GC: OR = 0.89, 95% CI: 0.69--1.16) (Figure [3A](#F3){ref-type="fig"}, Table [2](#T2){ref-type="table"}).
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###### Meta-analysis of the relationships between miR146a (rs2910164 G \> C) polymorphism and breast cancer risk

  Group                Included studies   Genotype models   OR (95% CI)         *Z*    *P*     Heterogeneity test   
  -------------------- ------------------ ----------------- ------------------- ------ ------- -------------------- --------
  Total                9 studies          C vs. G           0.90 (0.78, 1.05)   1.37   0.171   0                    73.50%
                                          CC vs. GG         0.86 (0.62, 1.20)   0.89   0.374   0.001                68.90%
                                          GC vs. GG         0.95 (0.86, 1.05)   0.98   0.326   0.061                46.40%
                                          CCcGC vs. GG      0.89 (0.75, 1.07)   1.26   0.209   0.005                63.40%
                                          CC vs. GG + GC    0.89 (0.69, 1.16)   0.88   0.379   0.005                63.90%
  Asian                4 studies          C vs. G           0.91 (0.78, 1.06)   1.24   0.213   0.112                49.90%
                                          CC vs. GG         0.93 (0.76, 1.13)   0.73   0.463   0.701                0.00%
                                          GC vs. GG         0.88 (0.66, 1.19)   0.83   0.407   0.08                 55.60%
                                          CC + GC vs. GG    0.86 (0.65, 1.14)   1.05   0.296   0.083                55.00%
                                          CC vs. GG + GC    0.93 (0.80, 1.07)   1.05   0.293   0.693                0.00%
  Caucasian            5 studies          C vs. G           0.92 (0.70, 1.20)   0.62   0.533   0                    83.40%
                                          CC vs. GG         0.85 (0.41, 1.80)   0.42   0.677   0                    83.50%
                                          GC vs. GG         0.93 (0.76, 1.14)   0.66   0.506   0.088                50.60%
                                          CC + GC vs. GG    0.91 (0.70, 1.19)   0.68   0.494   0.005                73.30%
                                          CC vs. GG + GC    0.88 (0.45, 1.74)   0.36   0.72    0                    80.70%
  Population-based     6 studies          C vs. G           0.87 (0.71, 1.07)   1.3    0.193   0                    83.10%
                                          CC vs. GG         0.85 (0.52, 1.38)   0.66   0.507   0                    80.30%
                                          GC vs. GG         0.94 (0.84, 1.04)   1.19   0.236   0.015                64.70%
                                          CC + GC vs. GG    0.85 (0.67, 1.08)   1.37   0.172   0.001                76.60%
                                          CC vs. GG + GC    0.89 (0.59, 1.36)   0.53   0.599   0.001                76.30%
  Hospital-based       3 studies          C vs. G           0.94 (0.81, 1.09)   0.87   0.383   0.771                0.00%
                                          CC vs. GG         0.87 (0.63, 1.20)   0.87   0.383   0.91                 0.00%
                                          GC vs. GG         1.05 (0.80, 1.37)   0.33   0.739   0.916                0.00%
                                          CC + GC vs. GG    0.99 (0.77, 1.29)   0.05   0.957   0.877                0.00%
                                          CC vs. GG + GC    0.85 (0.68, 1.08)   1.32   0.187   0.769                0.00%
  Sample-size \< 500   4 studies          C vs. G           0.88 (0.69, 1.14)   0.96   0.34    0.167                40.70%
                                          CC vs. GG         0.91 (0.57, 1.45)   0.41   0.684   0                    83.50%
                                          GC vs. GG         0.81 (0.62, 1.06)   1.53   0.127   0.133                46.50%
                                          CC + GC vs. GG    0.83 (0.58, 1.19)   1.01   0.313   0.123                48.10%
                                          CC vs. GG + GC    0.96 (0.66, 1.39)   0.22   0.827   0.797                0.00%
  Sample size ≥ 500    5 studies          C vs. G           0.91 (0.76, 1.10)   0.99   0.321   0                    83.80%
                                          CC vs. GG         0.85 (0.54, 1.32)   0.74   0.46    0.701                0.00%
                                          GC vs. GG         0.98 (0.87, 1.09)   0.43   0.667   0.097                49.00%
                                          CC + GC vs. GG    0.92 (0.74, 1.14)   0.77   0.441   0.005                73.00%

Notes: OR = Odds ratios; 95% CI = 95% confidence intervals.

Next, subgroup analysis was carried out according to race. No significant association was found in any genetic model for Asians and Caucasians. Subgroup analysis based on the source of controls revealed no significant association between any genetic model and either population-based or hospital-based groups; also, no associations were detected for sample sizes \< 500 and ≥ 500 (Table [2](#T2){ref-type="table"}).

Association between miRNA-196a2 rs11614913 polymorphism and BC susceptibility {#s2_3}
-----------------------------------------------------------------------------

The association between miR-196a2 rs11614913 polymorphism and the risk of BC was tested using the random-effects model, due to the presence of significant heterogeneity, for the allelic contrast model and the homozygote, dominant, and recessive models, while the fixed-effects model was used for the heterozygote model. A significantly decreased risk of BC was observed under the allelic contrast model and the recessive model (T vs. C, OR = 0.90, 95% CI: 0.81--1.00; TT vs. CC + TC, OR = 0.86, 95% CI: 0.74--1.00; Table [3](#T3){ref-type="table"}; Figure [3B](#F3){ref-type="fig"}).

###### Meta-analysis of the relationships between miR196a2 (rs11614913 C \> T) polymorphism and breast cancer risk

  Group                Included studies   Genotype models             OR (95% CI)                    *Z*               *P*                Heterogeneity test   
  -------------------- ------------------ --------------------------- ------------------------------ ----------------- ------------------ -------------------- -------------------
  Total                12 studies         **[T vs. C]{.ul}**          **[0.90 (0.81, 1.00)]{.ul}**   **[1.97]{.ul}**   **[0.049]{.ul}**   **[0]{.ul}**         **[69.00%]{.ul}**
                                          TT vs. CC                   0.83 (0.67, 1.02)              1.76              0.079              0.001                68.00%
                                          TC vs. CC                   0.92 (0.85, 1.00)              1.88              0.06               0.28                 16.70%
                                          TT + TC vs. CC              0.88 (0.78, 1.01)              1.88              0.06               0.015                53.10%
                                          **[TT vs. CC + TC]{.ul}**   **[0.86 (0.74, 1.00)]{.ul}**   **[2.01]{.ul}**   **[0.044]{.ul}**   **[0.008]{.ul}**     **[58.00%]{.ul}**
  Asian                6 studies          T vs. C                     0.85 (0.71, 1.02)              1.75              0.08               0.001                75.50%
                                          TT vs. CC                   0.78 (0.54, 1.12)              1.36              0.175              0.003                74.70%
                                          **[TC vs. CC]{.ul}**        **[0.85 (0.74, 0.99)]{.ul}**   **[2.17]{.ul}**   **[0.03]{.ul}**    **[0.135]{.ul}**     **[40.60%]{.ul}**
                                          TT + TC vs. CC              0.81 (0.63, 1.05)              1.59              0.112              0.021                62.40%
                                          TT vs. CC + TC              0.83 (0.67, 1.04)              1.65              0.099              0.014                67.90%
  Caucasian            4 studies          T vs. C                     0.91 (0.80, 1.03)              1.55              0.121              0.097                52.50%
                                          TT vs. CC                   0.79 (0.59, 1.08)              1.49              0.136              0.041                63.70%
                                          TC vs. CC                   0.95 (0.85, 1.06)              0.92              0.358              0.771                0.00%
                                          TT + TC vs. CC              0.94 (0.85, 1.05)              1.08              0.282              0.24                 28.70%
                                          TT vs. CC + TC              0.83 (0.64, 1.08)              1.38              0.167              0.063                58.80%
  Mix                  2 studies          T vs. C                     1.16 (0.72, 1.86)              0.62              0.538              0.042                75.90%
                                          TT vs. CC                   1.31 (0.53, 3.28)              0.58              0.559              0.049                74.20%
                                          TC vs. CC                   1.02 (0.80, 1.29)              0.15              0.877              0.196                40.10%
                                          TT + TC vs. CC              1.23 (0.63, 2.39)              0.6               0.548              0.084                66.60%
                                          TT vs. CC + TC              1.12 (0.65, 1.94)              0.41              0.678              0.129                56.60%
  Population-based     6 studies          T vs. C                     0.94 (0.85, 1.04)              1.21              0.228              0.126                41.90%
                                          TT vs. CC                   0.89 (0.74, 1.07)              1.28              0.2                0.211                31.60%
                                          TC vs. CC                   0.94 (0.84, 1.04)              1.22              0.224              0.476                0.00%
                                          TT + TC vs. CC              0.91 (0.81, 1.03)              1.44              0.151              0.263                22.70%
                                          TT vs. CC + TC              0.92 (0.81, 1.05)              1.23              0.22               0.339                11.70%
  Hospital-based       6 studies          T vs. C                     0.87 (0.72, 1.05)              1.41              0.159              0                    78.90%
                                          TT vs. CC                   0.76 (0.51, 1.13)              1.35              0.178              0                    78.30%
                                          TC vs. CC                   0.90 (0.79, 1.03)              1.5               0.132              0.132                41.00%
                                          TT + TC vs. CC              0.87 (0.68, 1.11)              1.11              0.266              0.007                68.60%
                                          TT vs. CC + TC              0.79 (0.60, 1.02)              1.79              0.073              0.007                68.60%
  Sample-size \< 500   4 studies          T vs. C                     1.07 (0.79, 1.45)              0.43              0.667              0.058                59.90%
                                          TT vs. CC                   1.43 (0.81, 2.52)              1.23              0.218              0.178                42.10%
                                          TC vs. CC                   0.96 (0.70, 1.31)              0.25              0.801              0.149                43.80%
                                          TT + TC vs. CC              1.07 (0.66, 1.76)              0.28              0.778              0.066                58.30%
                                          TT vs. CC + TC              1.21 (0.92, 1.59)              1.36              0.173              0.502                0.00%
  Sample size ≥ 500    8 studies          **[T vs. C]{.ul}**          **[0.87 (0.78, 0.96)]{.ul}**   **[2.74]{.ul}**   **[0.006]{.ul}**   **[0.002]{.ul}**     **[70.00%]{.ul}**
                                          **[TT vs. CC]{.ul}**        **[0.75 (0.61, 0.93)]{.ul}**   **[2.66]{.ul}**   **[0.008]{.ul}**   **[0.003]{.ul}**     **[68.00%]{.ul}**
                                          TC vs. CC                   0.92 (0.85, 1.00)              1.88              0.06               0.349                10.50%
                                          **[TT + TC vs. CC]{.ul}**   **[0.86 (0.76, 0.98)]{.ul}**   **[2.22]{.ul}**   **[0.026]{.ul}**   **[0.029]{.ul}**     **[55.20%]{.ul}**
                                          **[TT vs. CC + TC]{.ul}**   **[0.80 (0.69, 0.93)]{.ul}**   **[2.94]{.ul}**   **[0.003]{.ul}**   **[0.03]{.ul}**      **[54.90%]{.ul}**

Notes: OR = Odds ratios; 95% CI = 95% confidence intervals.

In subgroup analysis by race, a significantly decreased risk of BC was observed for Asians under the heterozygote model (TC vs. CC: OR = 0.85, 95% CI: 0.74--0.99). In Caucasians, in contrast, no association was detected between miR-196a2 rs11614913 and BC risk for any genotype model. Similarly, no relationship was found for any genotype model in the mixed-race subgroup. Results of subgroup analysis based on the source of controls showed no significant association between any genetic model and either population-based or hospital-based controls. We also found no significant association for sample size \< 500 under any genetic model, although a sample size ≥ 500 was associated with decreased BC risk in all models except the heterozygote (T vs. C: OR = 0.87, 95% CI: 0.78--0.96; TT vs. CC: OR = 0.75, 95% CI: 0.61--0.93; TT + TC vs. CC: OR = 0.86, 95% CI: 0.76--0.98; TT vs. CC + TC: OR = 0.80, 95% CI: 0.69--0.93; Table [3](#T3){ref-type="table"}).

Association between miRNA-499 rs3746444 polymorphism and BC susceptibility {#s2_4}
--------------------------------------------------------------------------

The association between miR-499 rs3746444 polymorphism and the risk of BC was examined by applying the fixed-effects model to assess all genetic models. A significantly increased risk of BC was observed for all genetic models (G vs. A: OR = 1.15, 95% CI: 1.07--1.24; GG vs. AA: OR = 1.32, 95% CI: 1.10--1.58; GA vs. AA: OR = 1.13, 95% CI: 1.03--1.24; GG + GA vs. AA: OR = 1.16, 95% CI: 1.06--1.27; GG vs. AA + GA: OR = 1.27, 95% CI: 1.06--1.51; Figure [3C](#F3){ref-type="fig"}).

Subgroup analysis was performed for the Asian population, where a positive association was identified under all genetic models (G vs. A: OR = 1.26, 95% CI: 1.14--1.40; GG vs. AA: OR = 1.60, 95% CI: 1.26--2.04; GA vs. AA: OR = 1.17, 95% CI: 1.02--1.33; GG + GA vs. AA: OR = 1.25, 95% CI: 1.10--1.41; GG vs. AA + GA: OR = 1.60, 95% CI: 1.27--2.02). In contrast, no association was found for Caucasians under any genetic model. Subgroup analysis by source of controls indicated an association with hospital-based controls under all genetic models (G vs. A: OR = 1.25, 95% CI: 1.11--1.41; GG vs. AA: OR = 1.48, 95% CI: 1.13--1.93; GA vs. AA: OR = 1.21, 95% CI: 1.02--1.43; GG + GA vs. AA: OR = 1.28, 95% CI: 1.09--1.49; GG vs. AA + GA: OR = 1.39, 95% CI: 1.08--1.79). Also, a significant association was identified between all genetic models and sample size ≥ 500 (G vs. A: OR = 1.15, 95% CI: 1.07--1.24; GG vs. AA: OR = 1.34, 95% CI: 1.12--1.62; GA vs. AA: OR = 1.11, 95% CI: 1.01--1.22; GG + GA vs. AA: OR = 1.15, 95% CI: 1.05--1.25; GG vs. AA + GA: OR = 1.32, 95% CI: 1.10--1.58), and between the dominant and heterozygote models and sample size \< 500 (GA vs. AA: OR = 2.33, 95% CI: 1.26--4.28; GG + GA vs. AA: OR = 1.91, 95% CI: 1.07--3.41; Table [4](#T4){ref-type="table"}).

###### Meta-analysis of the relationships between miR499 (rs3746444 A \> G) polymorphism and breast cancer risk

  Group                Included studies   Genotype models             OR (95% CI)                    *Z*               *P*                Heterogeneity test   
  -------------------- ------------------ --------------------------- ------------------------------ ----------------- ------------------ -------------------- -------------------
  Total                7 studies          **[G vs. A]{.ul}**          **[1.15 (1.07, 1.24)]{.ul}**   **[3.76]{.ul}**   **[0]{.ul}**       **[0.155]{.ul}**     **[35.90%]{.ul}**
                                          **[GG vs. AA]{.ul}**        **[1.32 (1.10, 1.58)]{.ul}**   **[2.99]{.ul}**   **[0.003]{.ul}**   **[0.239]{.ul}**     **[24.80%]{.ul}**
                                          **[GA vs. AA]{.ul}**        **[1.13 (1.03, 1.24)]{.ul}**   **[2.48]{.ul}**   **[0.013]{.ul}**   **[0.078]{.ul}**     **[47.20%]{.ul}**
                                          **[GG + GA vs. AA]{.ul}**   **[1.16 (1.06, 1.27)]{.ul}**   **[3.23]{.ul}**   **[0.001]{.ul}**   **[0.151]{.ul}**     **[36.40%]{.ul}**
                                          **[GG vs. AA + GA]{.ul}**   **[1.27 (1.06, 1.51)]{.ul}**   **[2.65]{.ul}**   **[0.008]{.ul}**   **[0.071]{.ul}**     **[48.30%]{.ul}**
  Asian                4 studies          **[G vs. A]{.ul}**          **[1.26 (1.14, 1.40)]{.ul}**   **[4.52]{.ul}**   **[0]{.ul}**       **[0.567]{.ul}**     **[0.00%]{.ul}**
                                          **[GG vs. AA]{.ul}**        **[1.60 (1.26, 2.04)]{.ul}**   **[3.84]{.ul}**   **[0]{.ul}**       **[0.795]{.ul}**     **[0.00%]{.ul}**
                                          **[GA vs. AA]{.ul}**        **[1.17 (1.02, 1.33)]{.ul}**   **[2.31]{.ul}**   **[0.021]{.ul}**   **[0.321]{.ul}**     **[14.20%]{.ul}**
                                          **[GG + GA vs. AA]{.ul}**   **[1.25 (1.10, 1.41)]{.ul}**   **[3.46]{.ul}**   **[0.001]{.ul}**   **[0.492]{.ul}**     **[0.00%]{.ul}**
                                          **[GG vs. AA + GA]{.ul}**   **[1.60 (1.27, 2.02)]{.ul}**   **[4.01]{.ul}**   **[0]{.ul}**       **[0.77]{.ul}**      **[0.00%]{.ul}**
  Caucasian            3 studies          G vs. A                     1.04 (0.93, 1.15)              0.69              0.493              0.794                0.00%
                                          GG vs. AA                   1.01 (0.76, 1.34)              0.06              0.955              0.605                0.00%
                                          GA vs. AA                   1.19 (0.88, 1.60)              1.1               0.271              0.026                72.50%
                                          GG + GA vs. AA              1.14 (0.89, 1.39)              0.96              0.335              0.113                54.20%
                                          GG vs. AA + GA              0.94 (0.71, 1.24)              0.45              0.65               0.194                39.10%
  Population-based     3 studies          G vs. A                     1.10 (1.00, 1.20)              1.96              0.05               0.114                53.90%
                                          GG vs. AA                   1.19 (0.93, 1.53)              1.4               0.162              0.124                52.00%
                                          GA vs. AA                   1.09 (0.97, 1.22)              1.48              0.139              0.327                10.60%
                                          GG + GA vs. AA              1.11 (0.99, 1.23)              1.81              0.07               0.229                32.10%
                                          GG vs. AA + GA              1.16 (0.90, 1.48)              1.16              0.247              0.116                53.50%
  Hospital-based       4 studies          **[G vs. A]{.ul}**          **[1.25 (1.11, 1.41)]{.ul}**   **[3.63]{.ul}**   **[0]{.ul}**       **[0.554]{.ul}**     **[0.00%]{.ul}**
                                          **[GG vs. AA]{.ul}**        **[1.48 (1.13, 1.93)]{.ul}**   **[2.87]{.ul}**   **[0.004]{.ul}**   **[0.474]{.ul}**     **[0.00%]{.ul}**
                                          **[GA vs. AA]{.ul}**        **[1.21 (1.02, 1.43)]{.ul}**   **[2.22]{.ul}**   **[0.027]{.ul}**   **[0.042]{.ul}**     **[63.30%]{.ul}**
                                          **[GG + GA vs. AA]{.ul}**   **[1.28 (1.09, 1.49)]{.ul}**   **[3.03]{.ul}**   **[0.002]{.ul}**   **[0.223]{.ul}**     **[31.50%]{.ul}**
                                          **[GG vs. AA + GA]{.ul}**   **[1.39 (1.08, 1.79)]{.ul}**   **[2.6]{.ul}**    **[0.009]{.ul}**   **[0.104]{.ul}**     **[51.30%]{.ul}**
  Sample-size \< 500   1 study            G vs. A                     1.19 (0.79, 1.78)              0.83              0.408              NA                   NA
                                          GG vs. AA                   0.80 (0.30, 2.12)              0.45              0.654              NA                   NA
                                          **[GA vs. AA]{.ul}**        **[2.33 (1.26, 4.28)]{.ul}**   **[2.71]{.ul}**   **[0.007]{.ul}**   **[NA]{.ul}**        **[NA]{.ul}**
                                          **[GG + GA vs. AA]{.ul}**   **[1.91 (1.07, 3.41)]{.ul}**   **[2.18]{.ul}**   **[0.029]{.ul}**   **[NA]{.ul}**        **[NA]{.ul}**
                                          GG vs. AA + GA              0.49 (0.20, 1.22)              1.53              0.126              NA                   NA
  Sample size ≥ 500    6 studies          **[G vs. A]{.ul}**          **[1.15 (1.07, 1.24)]{.ul}**   **[3.67]{.ul}**   **[0]{.ul}**       **[0.097]{.ul}**     **[46.40%]{.ul}**
                                          **[GG vs. AA]{.ul}**        **[1.34 (1.12, 1.62)]{.ul}**   **[3.13]{.ul}**   **[0.002]{.ul}**   **[0.226]{.ul}**     **[27.90%]{.ul}**
                                          **[GA vs. AA]{.ul}**        **[1.11 (1.01, 1.22)]{.ul}**   **[2.07]{.ul}**   **[0.039]{.ul}**   **[0.326]{.ul}**     **[13.90%]{.ul}**
                                          **[GG + GA vs. AA]{.ul}**   **[1.15 (1.05, 1.25)]{.ul}**   **[2.93]{.ul}**   **[0.003]{.ul}**   **[0.258]{.ul}**     **[23.50%]{.ul}**
                                          **[GG vs. AA + GA]{.ul}**   **[1.32 (1.10, 1.58)]{.ul}**   **[3.03]{.ul}**   **[0.002]{.ul}**   **[0.202]{.ul}**     **[31.10%]{.ul}**

Notes: OR = Odds ratios; 95% CI = 95% confidence intervals; NA = Not available.

Publication bias {#s2_5}
----------------

We utilized Begg\'s funnel plot and Egger\'s test to evaluate publication bias. No evidence of publication bias was found for the association between miR-146a rs2910164, miR-196a2 rs11614913, and miR-499 rs3746444 polymorphisms and BC susceptibility using Begg\'s funnel for the allelic contrast model (Figure [4](#F4){ref-type="fig"}). Egger\'s test also suggested no publication bias for the homozygote (rs2910164: *P* = 0.607; rs11614913: *P* = 0.624; rs3746444: *P* = 0.975), heterozygote (rs2910164: *P* = 0.298; rs11614913: *P* = 0.948; rs3746444: *P* = 0.207), dominant (rs2910164: *P* = 0.286; rs11614913: *P* = 0.942; rs3746444: *P* = 0.166) and recessive (rs2910164: *P* = 0.724; rs11614913: *P* = 0.728; rs3746444: *P* = 0.653) models.

![Begg\'s funnel plot for publication bias analysis under the allelic contrast model (**A**) miR-146a rs2910164, (**B**) miR-196a2 rs11614913, (**C**) miR-499 rs3746444).](oncotarget-08-68809-g004){#F4}

Sensitivity analysis {#s2_6}
--------------------

To examine the influence exerted by individual studies on the pooled ORs, sensitivity analysis in the allelic contrast model was performed by successively deleting each participant study. We confirmed that the omission of any single study did not significantly affect the overall results (Figure [5](#F5){ref-type="fig"}).

![Influence of individual studies on the overall OR under the allelic contrast model (**A**) miR-146a rs2910164, (**B**) miR-196a2 rs11614913, (**C**) miR-499 rs3746444).](oncotarget-08-68809-g005){#F5}

DISCUSSION {#s3}
==========

MiRNAs mediate degradation or translational repression by binding to the 3′UTR and 5′UTR of the target mRNA \[[@R2]\]. SNPs, the most common source of genetic sequence variation, can affect the function of miRNAs by altering primary transcript formation, pre-miRNA maturation, or miRNA-mRNA interactions \[[@R11], [@R37]\]. Even minor variations in miRNAs could have an enormous effect on the expression of different target genes and thus lead to susceptibility to several diseases including BC \[[@R38]\]. Murria Estal et al. identified miRNA profiles related to breast cancer features like node involvement, histological grade, ER, PR, and HER2 expression \[[@R39]\]. SNPs in miR-146a (rs2910164), miR-196a2 (rs11614913), and miR-499 (rs3746444) have been suggested to be predictive biomarkers for patients with BC \[[@R12], [@R14], [@R15], [@R26]--[@R28], [@R30], [@R31], [@R35], [@R40]\], although the studies in question provided inconsistent results. This lack of consensus prompted us to perform a comprehensive meta-analysis on the association of these three miRNAs polymorphisms and BC risk.

The miR-146a human gene is located on chromosome 5 at locus 5q34 and has been linked with BRCA1/BRCA2 activity. The SNP rs2910164 is located in the middle of the miRNA stem hairpin and leads to a change from a G:U pair to a C:U mismatch in the stem structure of the precursor molecule, altering the expression of mature miR-146a \[[@R41]\]. This SNP has been associated with the risk of various cancers, among them hepatocellular and bladder carcinomas \[[@R41], [@R42]\], evidencing also cancer-specific and ethnicity-dependent effects \[[@R43], [@R44]\]. Our analysis of miR-146a rs2910164, which included 4,441 cases and 3,899 controls from nine studies, revealed however no association with BC in both overall comparison and subgroup analysis by race, source of control, and sample size. In accordance with this conclusion, studies by Catucci et al. \[[@R14]\] and Alshatwi et al. \[[@R24]\] also failed to demonstrate a link between rs2910164 and BC risk.

The rs11614913 polymorphism in miR-196a2, located in the mature sequence of miR-196a-3P, may affect pre-miRNA maturation and confer diminished capacity to regulate target genes \[[@R11], [@R27]\]. Epidemiology studies have also revealed an association between rs11614913 and risk for multiple cancers; however, results were conflicting \[[@R42], [@R45]\]. Similarly, Linhares et al. \[[@R32]\] found that individuals carrying the CC genotype of rs11614913 in miR-196a2 had decreased BC risk, whereas Gao et al. \[[@R46]\] found instead a positive association between this genotype and BC risk. On the other hand, Dai et al. concluded that rs11614913 may reduce the risk of BC under the recessive model \[[@R47]\]. However, our meta-analysis involving twelve studies with 5,792 cases and 7,159 controls demonstrated an association of rs11614913 with decreased risk of BC both in the allelic contrast model and the recessive model. In subgroup analysis, a significant association was observed between rs11614913 and reduced risk of BC for the heterozygote model in Asians, and for all, except the heterozygote, genetic models when sample size ≥ 500. The discrepancies may derive from different sample sizes, races, and genetic backgrounds of the studies' groups.

Rs3746444, located at the 3p region of mature miR-499, involves a A:U to G:U mismatch in the stem structure of the precursor molecule, leading to altered processing and expression of the mature transcript \[[@R48]\]. The presence of this mismatch would affect Sox6 and Rod1 genes, which are important in the etiology of several cancers \[[@R49]\]. A number of studies investigating the association between rs3746444 and cancer risk have found that this SNP has distinct effects on different populations and cancer types. Dai et al. found that rs3746444 may be related to increased risk of BC under the allelic contrast, homozygote, and recessive models \[[@R47]\]. Our meta-analysis, assessing seven studies with 4,019 cases and 4,683 controls, showed that carriers of the rs3746444 GG genotype and GG + GA genotypes are at a significantly increased risk of developing BC when compared with those carrying the AA genotype. Also, Asians and hospital-based control subgroups demonstrated a significant association with increased risk of BC under all genetic models, but no significant association was found for Caucasians and for population-based source of control under any model. Thus, our results suggest oncogenic mechanisms are distinctly influenced by specific genetic backgrounds across populations.

Although the studies included in our meta-analysis differed from one another in numerous aspects, sensitivity analysis of miR-146a rs2710164, miR-196a2 rs11614913, and miR-499 rs3746444 indicated that the associations detected were not driven by any single one. Moreover, no publication bias was identified with either Begg\'s funnel plot or Egger\'s regression test. Finally, no limitations were imposed on our literature search, thus selection bias was well controlled.

Nevertheless, some limitations in this meta-analysis are noteworthy. Firstly, the number of included studies for the miR-499 rs3746444 polymorphism was limited. Secondly, there exists a certain degree of heterogeneity in some genetic models of rs2710164, rs11614913 and rs3746444. After subgroup analysis stratified by race, it could be established that heterogeneity was significantly reduced for Asians in some genetic models of rs11614913 and in all the genetic models of rs3746444. Thus, it could be assumed that the observed heterogeneity resulted, at least in part, from racial differences, which may have impacted the results of our study.

In conclusion, our results indicated that the rs2910164 (G \> C) polymorphism in miR-146a may not be associated with susceptibility to BC; the rs11614913 (C \> T) polymorphism in miR-196a2 is significantly associated with decreased BC risk; and the rs3746444 (A \> G) polymorphism in miR-499 is associated with increased BC risk, especially in Asians. Thus, rs11614913(C \> T) and rs3746444 (A \> G) appear to be both promising biomarkers to forecast BC risk and potential therapeutic targets. However, owing to the limitations mentioned above, these results should be treated with caution. To further verify and confirm these findings, well-designed, large scale case--control studies will be required.

MATERIALS AND METHODS {#s4}
=====================

Search strategy and selection criteria {#s4_1}
--------------------------------------

This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@R50]\]. To identify all published studies addressing the relationship between miRNA polymorphisms and BC risk, PubMed and Embase databases (last updated on July 20, 2016) were searched without publication type or date restrictions using the following keywords: breast cancer/carcinoma, miR-146a/rs2910164, miR-196a2/rs11614913, miR-499/rs3746444, and polymorphism/SNP/variation. The literature search was limited to English articles. We selected all potentially eligible studies for review.

Study selection and data extraction {#s4_2}
-----------------------------------

All the included studies were selected following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines \[[@R51]\]. Eligible studies met the following criteria: (1) assessed the relationship between miR-146a/-196a2/-499 polymorphisms and BC risk; (2) had a case-control design; (3) addressed histologically confirmed BC; (4) had sufficient genotype data for further calculating odds ratios (ORs) and their 95% confidence intervals (95% CIs); (5) met Hardy-Weinberg equilibrium (HWE) in the control group (*P* \> 0.05). Exclusion criteria included: (1) duplications of previous publications; (2) comments, meeting reports, reviews or editorials; (3) family-based studies of pedigrees; (4) studies with no detailed genotype data. When there were multiple publications from the same population, only the largest study was included. Study selection was done by two investigators independently, by screening the title, abstract and full-text. Any dispute was settled by discussion.

Data from eligible studies were extracted in duplicate by two investigators independently (Mu and Guo). Extracted data included author, year, country, race, genotyping method, source of control, genetic models of cases and controls, and *P* value for HWE (Table [1](#T1){ref-type="table"}). These two authors checked the extracted data and approved it by consensus. If dissent existed, an additional investigator (Liu) would intervene to settle the disagreement. The quality of selected studies was assessed by two or more investigators independently, according to the Newcastle-Ottawa Scale (NOS) criteria \[[@R52]\]. As per the latter, studies must ascertain or include: cases with independent validation (NOS01); representativeness of the cases (NOS02); selection of controls from community controls (NOS03); controls with no history of disease (endpoint) (NOS04); appropriate study controls for the most important study factor (NOS05); study controls for any additional factor (NOS06); secure record (NOS07); structured interview where interviewer is blind to case/control status (NOS08); same method of ascertaining exposure for cases and controls (NOS09); same non-response rate for both groups (NOS10). The maximum NOS score is 10 points, and studies scoring 6 or higher were included in the meta-analysis.

Statistical analysis {#s4_3}
--------------------

We calculated the *P* value of HWE in the control group using an online tool (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). The departure from HWE of SNP frequencies in the control group was assessed by *X^2^* test, and a *P* value \< 0.05 was regarded as significant. Odds ratios (ORs) and 95% confidence intervals (CIs) were obtained to evaluate the strength of the association between miR-146a/-196a2/-499 SNPs and susceptibility to BC. Pooled ORs were determined for the allelic contrast model (miR-146a: C vs G, miR-196a2: T vs C, miR-499: G vs A), homozygote model (miR-146a: CC vs GG, miR-196a2: TT vs CC, miR-499: GG vs AA), heterozygote model (miR-146a: GC vs GG, miR-196a2: TC vs CC, miR-499: AG versus AA), dominant model (miR-146a: CC + GC vs GG, miR-196a2: TT + TC vs CC, GG + AG vs AA), and recessive model (miR-146a: CC vs CG + GG, miR-196a2: TT vs TC + CC, miR-499:GG vs AG + AA). The statistical significance of the pooled OR was evaluated by *Z* test and a *P* value of \< 0.05 was regarded as significant. Inter-study heterogeneity was tested using a *X^2^*-based *Q*-test (with significance level *P* \< 0.1) and *I^2^* statistic (with values greater than 50% indicating significant heterogeneity) \[[@R53]\]. According to the result of the heterogeneity test, the random model was chosen to assess OR and 95% CI when *P* \< 0.05; conversely, the fixed model was selected when *P* \> 0.05. Subgroup analysis was performed by race, source of control, and sample size. Sensitivity analysis was performed to evaluate the effect of each study on the combined ORs by omitting individual studies one at a time. Publication bias was checked by Begg\'s funnel plots \[[@R54]\] and Egger\'s regression test \[[@R55]\]. An asymmetric plot and a *P* \< 0.05 for the Egger\'s test denoted a noteworthy publication bias. The trim-and-fill computation was used to estimate the effect of publication bias on the interpretation of the results \[[@R56]\]. Statistical analysis was conducted utilizing Stata12.0 Software.
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